Proteomics

Dataset Information

0

Phosphoproteomics of BYL719 (alpelisib)-Resistant T47D Human Breast Cancer Cell Line

ABSTRACT: The PI3Kalpha-specific inhibitor Alpelisib (BYL719) has been approved for the treatment of metastatic ER+/HER2- breast cancer patients in combination with Fulvestrant. After initial response, patients develop drug resistance and disease relapses. In order to identify signalling pathways contributing to the acquired resistance to BYL719 in breast cancer, we generated BYL719-resistant T47D cells and used them together with the parental cells to perform label-free quantitative phosphoproteomics.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell, Cell Culture

DISEASE(S): Breast Cancer

SUBMITTER: Kelvin Yip  

LAB HEAD: Antonella Papa

PROVIDER: PXD033956 | Pride | 2023-12-05

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
170818_Kelvin_Global_TD47_TiO_Par1.raw Raw
170818_Kelvin_Global_TD47_TiO_Par2.raw Raw
170818_Kelvin_Global_TD47_TiO_Par3.raw Raw
170818_Kelvin_Global_TD47_TiO_RP1.raw Raw
170818_Kelvin_Global_TD47_TiO_RP2.raw Raw
Items per page:
1 - 5 of 8
altmetric image

Publications

Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer.

Yip Hon Yan Kelvin HYK   Shin Sung-Young SY   Chee Annabel A   Ang Ching-Seng CS   Rossello Fernando J FJ   Wong Lee Hwa LH   Nguyen Lan K LK   Papa Antonella A  

NPJ precision oncology 20240126 1

Utility of PI3Kα inhibitors like BYL719 is limited by the acquisition of genetic and non-genetic mechanisms of resistance which cause disease recurrence. Several combination therapies based on PI3K inhibition have been proposed, but a way to systematically prioritize them for breast cancer treatment is still missing. By integrating published and in-house studies, we have developed in silico models that quantitatively capture dynamics of PI3K signaling at the network-level under a BYL719-sensitiv  ...[more]

Similar Datasets

Proteomics Identification of AGR2 interacting proteins in T47D cells using label-free quantification
2022-01-03 | PXD012690 | Pride
Proteomics Mitochondrial COA7 is a heme-binding protein with disulfide reductase activity, which is involved in the early stages of complex IV assembly
2022-03-23 | PXD031589 | Pride
Genomics Genome-Wide Progesterone Receptor Binding: Cell Type-Specific and Shared Mechanisms in Uterine Fibroids and Breast Cancer (ChIP-Seq)
2012-09-11 | E-GEOD-40724 | biostudies-arrayexpress
Proteomics RIME against TRPS1 in breast cancer cell lines
2018-06-12 | PXD009863 | Pride
Proteomics Mass Spectrometry of T47D cells treated with PTK6 PROTAC
| MSV000095916 | MassIVE
Genomics Temporal dynamic reorganization of 3D chromatin in hormone-induced breast cancer and endocrine resistance [T47D]
2019-04-09 | GSE119890 | GEO
Transcriptomics Support of a bi-faceted role of ERM-NM-2 in ERM-NM-1-positive breast cancer cells.
2013-11-21 | E-GEOD-45047 | biostudies-arrayexpress
Transcriptomics Gene expression of T47D-MTVL human breast cancer cells growing in normal conditions
2014-02-04 | E-GEOD-49236 | biostudies-arrayexpress
no omics defined Transcription profiling of breast cancer cells with TET-OFF regulated ERb expression treated with estradiol or ICI, an estrogen receptor antagonist
2007-12-17 | E-MEXP-969 | biostudies-arrayexpress
Proteomics Inclusion bodies formed by polyglutamine and poly(glycine-alanine) are enriched with distinct proteomes but converge in proteins that are risk factors for disease and involved in protein degradation
2020-08-18 | PXD018505 | Pride